Clover Biopharmaceuticals, a global clinical-stage biotech, has completed the enrolment of adult and elderly participants in its SPECTRA study, a global Phase II/III clinical trial examining the safety, efficacy and immunogenicity of the company’s Covid-19 vaccine, SCB-2019. Around 29,000 adults were enrolled in the trial, one of the most ethnically diverse Covid-19 clinical trials to date; over 45% of participants were from Asia, 45% were from Latin America, and the remainder were from Africa and Europe.
Batavia Biosciences and RocketVax, a subsidiary of Switzerland-based start-up Swiss Rockets, have joined forces to work on an investigational Covid-19 vaccine, RVX-13. Batavia said it is collaborating with the company to develop a clinical process capable of delivering 1,000 doses of material for the clinical trials. The vaccine is scheduled to enter Phase I clinical trials in 2022.
The World Health Organization (WHO) has recommended interleukin-6 receptor blockers for treatment of severely or critically ill Covid-19 patients, especially when administered along with corticosteroids. The updated guidelines for patient care are based on a living network meta-analysis initiated by WHO, the largest such analysis of the drugs to date. These are the first drugs found to be effective against Covid-19 since WHO recommended corticosteroids in September 2020. WHO has urged drug makers to reduce prices and make supplies of the drug available to low- and middle-income countries.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
